drugset / Trial / NCT03010631

Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers

NCT03010631 ↗

Phase 3 Completed 49 enrolled Sucampo Pharma Americas, LLC Takeda · collab
RandomizedCrossoverOpen-labelTreatment

Summary

A study to compare the pharmacokinetics and food-effect bioavailability of sprinkle formulation of lubiprostone, as compared to lubiprostone capsules in healthy volunteers.

Timeline

Start
2016-11-16
Primary completion
2016-12-23
Completion
2017-05

Outcome

Missed primary endpoint

paper Despite the significant improvement in SBM counts vs placebo, the sprinkle formulation did not demonstrate bioequivalence to the capsule formulation in either pharmacodynamic or PK key parameters. PMID 33834354 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Lubiprostone Small molecule 48 ug Oral

Indications

No indication recorded.